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died (64.2%, overall mortality rate 31%); however, no statis-
tical significance was found ( p < 0.7). Of the remaining 15 
patients (51.7%) with noninfectious triggers, 11 died (73.3%, 
overall mortality rate 37.9%); again there was no statistical 
significance ( p < 0.7). Twenty-four patients (83%) developed 
acute kidney injury (overall mortality rate 65.5%;  p < 0.022) 
at the 28-day and 90-day follow-up. Twelve patients had 
acute kidney injury requiring renal replacement therapy 
(41.37%; overall mortality rate 37.9%;  p < 0.043). Hepatic 
transplant was performed in 3 patients, with a 100% sur-
vival at the 28-day and 90-day follow-up ( p < 0.023). Higher 
grades of ACLF were associated with increased mortality 
( p < 0.02; overall mortality 69%).  Conclusions: ACLF is a het-
erogeneous syndrome with a variety of precipitant factors 
and different grades of extrahepatic involvement. Most cas-
es will have some degree of renal dysfunction, with an in-
creased risk of mortality. Hepatic transplant is an efficient 
form of therapy for this syndrome. 
 © 2017 Sociedade Portuguesa de Gastrenterologia
Published by S. Karger AG, Basel 
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 Abstract 
 Acute-on-chronic liver failure (ACLF) is a syndrome charac-
terized by an acute deterioration of a patient with cirrhosis, 
frequently associated with multi-organ failure and a high 
short-term mortality rate. We present a retrospective study 
that aims to characterize the presentation, evolution, and 
outcome of patients diagnosed with ACLF at our center over 
the last 3 years, with a comparative analysis between the 
group of patients that had ACLF precipitated by infectious 
insults of bacterial origin and the group of those with ACLF 
triggered by a nonbacterial infectious insult; the incidence 
of acute kidney injury and its impact on the prognosis of 
ACLF was also analyzed. Twenty-nine patients were en-
rolled, the majority of them being male (89.6%), and the 
mean age was 53 years. Fourteen patients (48.3%) devel-
oped ACLF due to a bacterial infectious event, and 9 of them 
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 Doença Hepática Crónica Agudizada: 
Revisão da Experiência de um Centro Português 
de Referenciação 
 Palavras Chave 
 Doença hepática crónica agudizada · Lesão renal aguda · 
Falência multiorgânica · Transplante hepático 
 Resumo 
 A Doença Hepática Crónica Agudizada/Falência é um sín-
drome caracterizado por uma deterioração aguda de um 
doente com cirrose, frequentemente associada com falên-
cia multiorgânica e elevada mortalidade a curto prazo. 
Apresentamos estudo retrospetivo que teve como objetivo 
caracterizar a apresentação, evolução e prognóstico de 
doentes diagnosticados com Doença Hepática Crónica 
Agudizada/Falência no nosso Centro nos últimos 3 anos, 
comparando o grupo de doentes que tiveram Doença He-
pática Crónica provocada por infeções bacterianas e os 
doentes com Doença Hepática Crónica Agudizada/Falên-
cia desencadeada por precipitantes que não a infeção bac-
teriana; foi também analisada a incidência de lesão renal 
aguda e o seu impacto no prognóstico na Doença Hepática 
Crónica Agudizada/Falência. Vinte e nove doente foram in-
cluídos no estudo, a maioria do género masculino (89.6%), 
idade media de 53 anos. Catorze doentes (48.3%) desenvol-
veram Doença Hepática Crónica Agudizada devido a infe-
ção bacteriana, 9 dos quais faleceram (64.2%, mortalidade 
global 31%), contudo, sem significado estatístico ( p < 0.7); 
dos restantes 15 (51.7%) sem infeção bacteriana, 11 falece-
ram (73.3%, mortalidade global 37.9%), também sem signi-
ficado estatístico ( p < 0.7%). Vinte e quatro doentes (83%) 
desenvolveram lesão renal, mortalidade global de 65.5% 
( p < 0.022) aos 28 e 90 dias de seguimento. Doze doentes 
desenvolveram lesão renal aguda com necessidade de te-
rapêutica de substituição da função renal (41.37%), morta-
lidade global de 37.9% ( p < 0.043). O transplante hepático 
foi realizado em 3 doentes, com uma sobrevida de 100% 
aos 28 e 90 dias de seguimento ( p < 0.023); Graus elevados 
de Doença Hepática Crónica Agudizada estão associadas a 
mortalidade mais elevada ( p < 0.02); mortalidade global de 
69%. Conclusions: A Doença Hepática Crónica Agudizada é 
um síndrome heterogéneo, com uma variedade de fatores 
precipitantes e diferentes graus de envolvimento extra-he-
pático; a maioria das situações estará associada a disfunção 
renal, com aumento do risco de mortalidade; O transplante 
hepático será uma eficaz de tratamento deste síndrome.
 © 2017 Sociedade Portuguesa de Gastrenterologia
Publicado por S. Karger AG, Basel 
 Introduction 
 Acute-on-chronic liver failure (ACLF) is a recently 
recognized entity defined by an acute deterioration of a 
patient with cirrhosis, either compensated or at least rela-
tively stable decompensated  [1] . ACLF is frequently as-
sociated with multi-system organ failure, consequent re-
quirement of organ supports, and a high short-term mor-
tality rate  [1, 2] .
 Recently, the World Gastroenterology Organisation, 
the European Association for the Study of Liver Diseases 
(EASL), the American Association for the Study of Liver 
Diseases (AASLD), and the Asian-Pacific Association for 
the Study of the Liver (APASL) defined ACLF as a syn-
drome that occurs in patients with known chronic liver 
disease, with or without cirrhosis, characterized by acute 
decompensation of the liver (ascites, encephalopathy, 
gastrointestinal bleeding, and/or bacterial infection), and 
one or more extrahepatic organ dysfunction (kidney, 
brain, coagulation, circulation, and/or lung), with a high 
28-day mortality rate (at least 15%) and up to 3 months 
from the onset  [2–6] .
 The CANONIC (Acute-on-Chronic Liver Failure in 
Cirrhosis) study is currently the largest prospective mul-
ticenter study made on ACLF; it documented a preva-
lence of ACLF of 30.9%, with a high short-term mortal-
ity of 33% at 28 days and 51% at 90 days. The study also 
suggested an important role of dysregulated inflamma-
tion in the pathophysiology of this syndrome, since the 
degree of inflammatory reaction, which was estimated by 
leukocyte and C-reactive protein levels, was found to be 
an important parameter regarding the severity and out-
come of ACLF. It was found that all patients with ACLF 
had leukocytosis and elevated levels of C-reactive pro-
tein, which was due to an inflammatory trigger such as 
bacterial infections and severe alcoholic hepatitis in 57% 
of the patients, or to yet unidentified mechanisms in the 
remaining 43%, which suggests an altered response to 
injury and immune dysfunction that leads to an inappro-
priate inflammatory response. In the CANONIC trial, 
the sequential organ failure assessment was used to iden-
tify organ failure; however, it was modified so that spe-
cific features of cirrhosis were taken into consideration. 
A 4-grade score was used to stratify patients with ACLF 
in accordance to the number of organ failures, grade 0 
being the absence of organ failure and grades 1–3 those 
for patients with 1, 2, and >3 organ failures. Moreover, 
another important data from the CANONIC study was 
that kidney dysfunction alone (defined as serum creati-
nine [Scr] ranging from 1.5 to 1.9 mg/dL) is associated 
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with a 28-day mortality greater than the predefined lim-
it required for the diagnosis of ACLF. Contrariwise, any 
other single-organ failure was only associated with a 28-
day mortality >15% when it occurred with concomitant 
renal injury  [3] .
 ACLF can be triggered by intrahepatic or extrahepatic 
insults. Nonetheless, extrahepatic insults can be linked to 
a different outcome  [7] . A potential precipitating event of 
the syndrome may not be identifiable  [3] .
 Due to the growing recognition of ACLF as a distinct 
syndrome, we performed a retrospective study where we 
characterize the clinical presentation, evolution, and out-
come of a population of patients with the diagnosis of 
ACLF at our center over the last 3 years, with a compara-
tive analysis between the group of patients that had ACLF 
precipitated by infectious insults of bacterial origin and 
the group of those in whom a nonbacterial infectious in-
sult was responsible for the development of the syndrome; 
the study also had the objective to analyze the incidence 
of acute kidney injury (AKI) and its impact on the prog-
nosis of ACLF.
 Materials and Methods 
 ACLF was diagnosed in accordance with the Chronic Liver 
Failure-Sequential Organ Failure Assessment (CLIF-SOFA)  [3] .
 AKI was diagnosed using the adaptation of the Acute Kidney 
Injury Network (AKIN) criteria to define AKI in patients with cir-
rhosis, as proposed by the Acute Dialysis Quality Initiative (ADQI) 
along with members of the International Club of Ascites (ICA). 
According to these criteria, AKI is defined as an increase in the Scr 
level of  ≥ 0.3 mg/dL within 48 h or an increase in the Scr level by 
 ≥ 50% from baseline that is known or presumed to have occurred 
within the prior 7 days  [8, 9] .
 Inclusion criteria were known cirrhosis in patients admitted to 
the intensive care unit (ICU) of our center with the diagnosis of 
ACLF confirmed by clinical and analytical data between 2013 and 
2015.
 Exclusion criteria were patient ages <18 and >85 years; prior 
liver and/or kidney transplant; end-stage renal disease already on 
a regular dialysis program; pregnancy; hepatocellular carcinoma 
outside the Milan criteria, and known human immunodeficiency 
virus infection.
 The model for end-stage liver disease (MELD) scoring system 
was used to estimate the severity of the hepatic dysfunction  [10] .
 The outcome of patients was evaluated 28 and 90 days after ICU 
admission.
 Different causes of decompensation were categorized into bac-
terial infectious insults, such as pneumonia, spontaneous bacterial 
peritonitis (SBP), and urinary tract infections, and nonbacterial 
infectious insults, such as active hepatitis C virus replication 
(HCV), upper gastrointestinal bleeding, portal vein thrombosis, 
acute cardiac failure, and carcinoma of the ampulla of Vater.
 Statistical analysis was performed with SPSS, and the Kruskal-
Wallis test and the Exact Fisher test were used.
 A comparative analysis was made between the groups of pa-
tients that had ACLF precipitated by intrahepatic insults and those 
in whom an extrahepatic insult was responsible for the develop-
ment of the syndrome.
 We also compared the MELD score with the different grades of 
ACLF that were estimated in this series to establish a possible as-
sociation between the severity of chronic liver disease and the pro-
gression of ACLF.
 The incidence of AKI and the need of renal replacement ther-
apy (RRT) were determined to analyze its impact on the prognosis 
of ACLF.
 A comparative analysis between survival and liver transplant 
was made; we also compared the outcome of patients in the differ-
ent grades of ACLF to determine the impact of the increasing sys-
temic involvement on the prognosis of the syndrome.
 Results 
 Sixty-two patients were admitted in the ICU with a 
new episode of acute decompensation of cirrhosis; a total 
of 29 patients met the inclusion criteria.
 Of these 29 patients, 89.6% were male ( n = 26), the 
mean age was 53 years (47.99 ± 58.01), the median age 
was 50 years, the minimum age was 18 years, and the 
maximum age was 81 years. 
 Regarding the etiology of cirrhosis, 12 patients had al-
coholic liver cirrhosis (41.4%); 7 (24.1%) had cirrhosis 
due to both HCV infection and alcoholic liver cirrhosis; 
 Table 1.  Bacterial infectious and nonbacterial infectious insults identified as causes of ACLF
Bacterial infectious insult Nonbacterial infectious insult
Pneumonia (n = 8; 27.5%) Upper gastrointestinal bleeding (n = 11; 37.9%)
Spontaneous bacterial peritonitis (n = 2; 6.9%) Acute cardiac failure (n = 1; 3.44%)
Urinary tract infections (n = 4; 13.8%) Carcinoma of the ampulla of Vater (n = 1; 3.44%)
Active hepatitis C virus replication (n = 1; 3.44%)
Portal vein thrombosis (n = 1; 3.44%)
 Acute-on-Chronic Liver Failure  GE Port J Gastroenterol 2018;25:18–23 
DOI: 10.1159/000478988
21
6 patients had liver disease due to HCV infection alone 
(20.7%); 1 case (3.44%) had cirrhosis due to primary scle-
rosing cholangitis; 1 patient (3.44%) due to cryptogenic 
hepatic cirrhosis; 1 patient (3.44%) had hepatocellular 
carcinoma, and the final case had cirrhosis due to both 
hemochromatosis and alcoholic liver diseases.
 ACLF was triggered by a bacterial infectious insult in 
14 (48.3%) patients, and nonbacterial infectious insults 
were responsible for the development of ACLF in the re-
maining 15 (51.7%) patients, as demonstrated in  Table 1 . 
 The Kruskal-Wallis test ( Fig. 1 ) was used to study a 
possible association with the increase of the MELD score 
and the different grades of ACLF; we observed that the 
MELD distribution varied in accordance with the ACLF 
grades 1, 2, and 3; however, this was more evident by 
comparing ACLF grade 1 with 2 and grade 1 with 3 ( p < 
0.037) and less notorious when comparing ACLF grades 
2 and 3.
 Twenty-four patients (83%) developed AKI, and this 
was associated with an overall mortality rate of 65.5% at 
the 28-day and 90-day of follow-up ( n = 19;  p < 0.022).
 AKI requiring RRT was verified in 12 patients 
(41.37%), with an overall mortality rate of 37.9 % ( p < 
0.043) at 28 90 days.
 Fifteen patients (51.7%) had ACLF due to a nonbacte-
rial infectious injury, 11 (73%) of whom died (overall 
mortality rate of 37.9%), but without statistical signifi-
cance ( p < 0.7). Of the remaining 14 patients with bacte-
rial infectious insults, 9 died (64.3%, overall mortality rate 
31%), again without statistical significance ( p < 0.7%). 
The results were identical at 28 and 90 days in both 
groups. However, all patients with ACLF due to infec-
tious insults developed AKI and ACLF, and statistical sig-
nificance was found ( n = 14;  p < 0.042).
 Hepatic transplant was performed in 3 patients, with a 
100% survival at the 28-day and 90-day follow-up. De-
spite the reduced number of patients, statistical signifi-
cance was noted ( p < 0.023).
 Higher grades of ACLF were associated with increased 
mortality ( p < 0.02), as illustrated in  Table 2 . Identical re-
sults were noted at 28 and 90 days; and the overall mortal-
ity was 69%. 
 Discussion 
 The authors present the first series in Portugal of pa-
tients diagnosed with ACLF, and a heterogeneous popu-
lation was identified. This syndrome can develop in pa-
tients with cirrhosis with variable etiologies, although 
most of those observed had alcoholic liver cirrhosis, 
which was in accordance with other series  [3] . 
 ACLF is considered a dynamic process, which may be 
reversible in approximately half of the cases or it can 
progress to a life-threatening condition  [7] . Nevertheless, 
patients with a diagnosis of ACLF remain a diverse popu-
lation, with different types of precipitating events and 
variations in the etiology of cirrhosis and presentation of 
organ failure  [3, 11] .
 A variety of insults can precipitate ACLF, both of he-
patic or extrahepatic origin; the main cause of acute de-
compensation of cirrhosis in this study was bacterial in-
fection, which is described as the leading cause of hospi-
talization, decompensation, and mortality in cirrhosis 
 [12] .
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 Table 2.  Outcome of ACLF
ACLF  Outcome at 28 and 90 days Total
 alive deceased
Grade 1 4 0 4
Grade 2 4 7 11
Grade 3 1 13 14
Total 9 20 29
 ACLF, Acute-on-chronic liver failure.
 Fig. 1. Kruskal-Wallis test. ACLF, acute-on-chronic liver failure; 
MELD, model for end-stage liver disease. 
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 The MELD score varied significantly between grade 1, 
grade 2, and grade 3 ACLF but less significantly between 
grade 2 and grade 3 ACLF. This may be due to the fact 
that ACLF is a systemic disorder, and the MELD is an in-
dicator of hepatic dysfunction. As the syndrome pro-
gresses, its outcome may be associated more with the de-
gree of multi-organ failure than with the severity of the 
hepatic disease.
 We were not able to establish a difference between the 
outcome of ACLF caused by bacterial infectious insults 
ACLF triggered by nonbacterial infectious mechanisms. 
However, all patients with ACLF caused by infections de-
veloped AKI; this may be due to an increased systemic 
inflammation triggered by the infection, which has been 
suggested to contribute to the pathophysiological hall-
marks responsible for the development of structural AKI 
in patients with ACLF  [13] .
 AKI was detected in most cases ( n = 24; 83%), with a 
high 28-day and 90-day mortality; half of them ( n = 12) 
required RRT, with a mortality rate of 92% in this sub-
group of patients.
 AKI in patients with cirrhosis may be due to function-
al changes, which are induced by renal hypoperfusion, 
accounting for approximately two-thirds of all cases; this 
is mostly due to diuretic therapy and lactulose-associated 
diarrhea, reversible in almost half of the situations. The 
remaining cases are classified as hepatorenal syndrome or 
volume non-responsive AKI. Structural changes, such as 
glomerulonephritis, acute tubular necrosis, and other 
forms of tubular dysfunction or parenchymal disease ac-
count for the remaining one-third of the cases of AKI in 
cirrhosis.
 Contrariwise, in patients with ACLF, AKI secondary 
to structural changes is more common, this being due to 
the presence of inflammation and infection in the patho-
physiological mechanisms of renal dysfunction in ACLF 
 [13] . A recent report in the histological findings of 43 
post-mortem kidney biopsies of patients with ACLF and 
decompensated cirrhosis showed that the “bile cast ne-
phropathy”, an entity characterized by renal tubular in-
jury secondary to direct toxic damage caused by the ele-
vated levels of bilirubin and bile acids, is significantly 
more common in ACLF than in patients with cirrhosis 
 [14] .
 The distinction between functional and structural AKI 
is of paramount importance when the hypothesis of he-
patic transplant is being considered: functional AKI will 
probably solve with hepatic transplant alone; however, 
structural AKI may require simultaneous liver-kidney 
transplant  [7, 15] .
 Conclusions 
 ACLF is a heterogeneous syndrome with a variety of 
etiologies for cirrhosis, precipitant factors, and different 
grades of extrahepatic organ involvement. Early diagno-
sis and quick reference to a hepatic transplant center 
could be crucial in the management and success of this 
clinical situation. Most cases will have some degree of re-
nal dysfunction, with an increased risk of mortality. He-
patic transplant is an efficient form of therapy for this 
syndrome.
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